Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Novartis
Novartis
Anti-aging startup ResTORbio gets $40M to fuel Phase IIb study
Endpoints
Thu, 11/30/17 - 11:03 am
anti-aging
clinical trials
ResTORbio
Novartis
RTB101
Incoming Novartis CEO On $475,000 Cancer Therapy: 'No Question That The List Price Raises Eyebrows'
Forbes
Thu, 11/30/17 - 09:56 am
Novartis
drug pricing
cancer
Kymriah
Pharma CEOs
Vas Narasimhan
One big Novartis takeaway from Entresto's slow start? Heart failure doesn't work like oncology
Fierce Pharma
Wed, 11/29/17 - 11:40 am
Novartis
Entresto
drug launches
heart failure
oncology
Novartis looks to poach Advair patients with positive Ultibro switching data
Fierce Pharma
Mon, 11/27/17 - 10:42 am
Novartis
Advair
Ultibro Breezhaler
GSK
COPD
With Novartis closing in, Regeneron scraps Eylea combo drug in a major setback
Endpoints
Mon, 11/27/17 - 09:18 am
Novartis
Regeneron
Eylea
RTH258
nesvacumab
Bayer
Pfizer's Ibrance, Novartis' Kisqali go to battle in England after discounts twin NICE recommendations
Fierce Pharma
Thu, 11/16/17 - 11:07 am
Pfizer
Ibrance
Novartis
Kisqali
England
breast cancer
UK
NICE
What to expect from Vas Narasimhan, next Novartis CEO
GoinPharma
Tue, 11/14/17 - 07:46 am
Novartis
Pharma CEOs
Vas Narasimhan
Prepping a case for canakinumab, Novartis tries to stake out a high-value segment of huge cardio market
Endpoints
Mon, 11/13/17 - 08:51 pm
Novartis
canakinumab
heart disease
heart attack
Novartis spotlights its top 4 blockbuster late-stage pipeline projects
Endpoints
Mon, 11/13/17 - 09:35 am
Novartis
RTH258
wet age-related macular degeneration
AMG 334
migraines
Cosentyx
ACZ885
Novartis outlines its full case on why RTH258 can carve out a big piece of the AMD market held by Regeneron
Endpoints
Fri, 11/10/17 - 10:23 pm
Novartis
RTH258
wet age-related macular degeneration
Regeneron
Novartis strengthens autoimmune indications for Cosentyx
PM Live
Fri, 11/10/17 - 10:21 pm
Novartis
Cosentyx
autoimmune disease
psoriatic arthritis
ankylosing spondylitis
Novartis takes fight to Pfizer's Ibrance with new Kisqali data
Yahoo/Reuters
Wed, 11/8/17 - 10:10 am
Novartis
Pfizer
Ibrance
Kisqali
breast cancer
With new FDA nod, Roche's Alecensa set to challenge Pfizer, Novartis in first-line lung cancer
Fierce Pharma
Tue, 11/7/17 - 10:55 am
Roche
Alecensa
Pfizer
Novartis
lung cancer
Zykadia
Xalkori
9 Notable Biotechs Presenting At This Year's ASH Meeting
Yahoo
Tue, 11/7/17 - 09:56 am
ASH
Bluebird Bio
LentiGlobin
Ziopharm Oncology
Bellicum
BPX-501
Spark Therapeutics
SPK-8011
Biomarin
BMN 270
Juno Therapeutics
CAR-T
Novartis
Geron
imetelstat
Immunogen
IMGN632
IMGN779
Novartis seeks European approval for cell therapy Kymriah
Reuters
Mon, 11/6/17 - 09:25 am
Novartis
Europe
CAR-T
Kymriah
diffuse large B-cell lymphoma
acute lymphoblastic leukemia
Novartis and Amgen launch new Alzheimer’s study
Endpoints
Thu, 11/2/17 - 10:12 pm
Novartis
Amgen
Alzheimer's disease
CNP520
clinical trials
Juno Therapeutics' 3rd Quarter Boosted by Potential Rival Novartis
Yahoo/Motley Fool
Thu, 11/2/17 - 09:26 am
Juno Therapeutics
earnings
Novartis
Novartis Weighs Sale of Dermatology Generics Business
Bloomberg
Wed, 11/1/17 - 09:39 am
Novartis
dermatology
M&A
Novartis hustles along another FDA application for CAR-T star, tackling Gilead head on
Endpoints
Tue, 10/31/17 - 09:38 am
Novartis
FDA
CAR-T
Kymriah
diffuse large B-cell lymphoma
Latecomer Verzenio stands out from Ibrance, Kisqali in launch's early days: Lilly
Fierce Pharma
Mon, 10/30/17 - 10:00 am
Verzenio
Ibrance
Kisqali
drug launches
breast cancer. Eli Lilly
Pfizer
Novartis
Pages
« first
‹ previous
…
60
61
62
63
64
65
66
67
68
…
next ›
last »